Pkeday.

Mainboard · RHP filed 2026-10-09

Sahajanand Medical Technologies Limited

FIRST LOOK 19 Oct 2026 · process v3.0-sandbox

Worth the full assessment, carried there by one business rather than by the company as a whole: the heart-valve line scores 4 out of 5 on its market and 3 out of 5 on its ability to win, while the stent business that is 61% of revenue has been flat in India for three years and every European approval but one expires on 31 December 2027.

Rs 327 to Rs 344 a share · bids 15 to 19 Oct 2026, listing date not fixed · Rs 476 cr at the top, every rupee of it existing owners selling: there is no fresh issue

A Surat company, founded in 2001, that makes the devices a cardiologist pushes through an artery to fix a heart: drug-coated stents that hold a blocked vessel open, balloons, a replacement aortic valve and plugs for holes in the heart. Three plants, two in India and one in Thailand, and sales in 77 countries last year.

The bearings

Market cap at the top of the band
About Rs 3,497 cr. Rs 3,324 cr at the floor. The share count does not change, because nothing new is issued.
Price against profit
53 times last year's profit at the top of the band, 51 times at the floor. The document offers only two listed companies to compare with - Poly Medicure at 51 times and Laxmi Dental at 36, averaging 44 - and neither of them makes heart implants, so the comparison is thin. On other measures: 2.9 times last year's sales and 5.5 times book value.
Fresh money against shares sold
None of it is fresh. All Rs 476 cr goes to five existing holders, so the company receives nothing and no part of the business is funded by this offer. The founding family's trust sells 7% of its own holding; a promoter-group individual sells 49% of his, having paid 63 paise a share. Of the three investment firms, Samara sells 22% of its holding, Morgan Stanley's fund 9%, and a Kotak fund 22% - the Kotak fund having paid Rs 262 a share, the closest of any seller to the price being asked.
What the fresh money does
Nothing, because there is none. The costs of the offer are shared among the selling holders in proportion to what each sells; the company pays them first and is reimbursed.
Promoter holding
40.8% before the offer, 36.2% after. Worth noting either way: the promoters are not the largest block of shares. Samara Capital holds 29.6% before and about 23.2% after, and the four investment holders together hold 51.6% before and about 41.9% after.
The last private price
Rs 365 a share, in March 2025, and the largest single trade at that price was a Rs 40 cr block bought by Ashish Kacholia. The company also issued shares to its employee trust at Rs 365 in September 2026. So the Rs 344 top of this band is 5.8% below what private buyers paid eighteen months ago. No trade above 5% of the company changed hands in the eighteen months before the filing.
Last year's revenue and profit
Revenue Rs 1,210 cr, up 18%. Profit Rs 69 cr, against Rs 25 cr the year before and a Rs 7 cr loss the year before that. Operating profit margin 14.1%, which is below every company the document compares it with. Borrowings Rs 321 cr against Rs 79 cr of cash.
Lead managers
Four: Motilal Oswal, Avendus, HSBC and Nuvama. Auditor Deloitte Haskins & Sells, unchanged for three years.

What the company sells

Stents and balloons

61% of revenue · +10% last year, and +9% a year over two years - the slowest of the three

Drug-coated metal stents, led by Supraflex Cruz, and the balloons used to open a vessel before one goes in. Sold to hospitals and government tenders, directly in Europe and India and through distributors elsewhere.

The market3/5

The market this business actually sells into grows about 5% a year, well below the 8% the document's own industry chapter puts on its headline, and global spending on these stents actually fell slightly between 2019 and 2025. The reason is simple: the change the company rode is over, because at least 90 of every 100 stents fitted are already drug-coated, so there is no switch left to win. India should be the exception and is not - the Indian market is growing in the number of procedures, but the company's Indian revenue has been flat in rupees for three years and fell last year, and its share of Indian drug-coated stent volume has slipped from about 31% around 2021 to about 25% now. All the growth is in Europe, where this business grew about 33% a year over two years against a European market growing under 1%. It has barely scratched the markets it can actually reach, holding roughly 3% of them, but the two largest markets in the world are closed to it: it gave up on the United States by choice, and it does not sell in China at all.

Right to win3/5

There is a real advantage here and it is possible to name: the company manufactures in India and Thailand, and the industry report in its own document says that lets it price 20% to 30% below what else is on the shelf. Its clinical record - 35 completed trials on 28,383 patients, published in The Lancet - is the licence to bid; the discount wins the tender. Six of its own European sales companies and two distributors it bought are the channel that carries it, and the German, Polish and Spanish subsidiaries have grown 37% to 68% a year. But it is a price-and-channel advantage rather than a better product: its trials showed its stent was as good as the market leader's, not better. That is why the same company that wins European tenders is losing India, where one statutory price ceiling applies to everyone and there is no price left to compete on. And the advantage is not exclusive - Translumina manufactures in India and Germany across 60-odd countries, and Chinese makers sit in the same cost class. The clearest evidence of the limit is Meril, an Indian competitor under the identical Indian price ceiling, whose comparable business is about two and a half times this one's and grew 40% last year. Every strength we could evidence here, Meril also has.

Heart valves and heart-hole plugs

17% of revenue · +29% last year, and +36% a year over two years

The Hydra replacement aortic valve, threaded up an artery instead of opened-chest surgery, and the Cocoon plugs that close holes in the heart. Both made at one plant in Thailand.

The market4/5

Replacing a heart valve through an artery instead of opening the chest is a genuine shift with a decade or more left in it: over a million European patients with severe aortic narrowing are eligible and fewer than one in five is treated that way, and procedures worldwide have gone from 20,000 in 2010 to more than 200,000 in 2024. It does not translate into fast revenue growth, though, because health services take the benefit as lower prices - European revenue in this market grows under 5% a year. What earns the higher score is what the company has done inside it: it tripled the valves it made in two years, from 686 to 1,784, and went from selling in 21 countries to 35, while that market grew under 10%. It holds about 1% of European procedures and its Thai line is only 59% used, so it can grow further without raising money. India is the opposite and is not the opportunity it looks: the whole Indian market reaches only about USD 94m by 2030, the government insurance scheme caps a family at Rs 5 lakh a year against an implant costing Rs 12.84 lakh, and 82 paise of every rupee of Indian health spending comes out of patients' pockets.

Right to win3/5

Three advantages here are evidenced rather than asserted. Britain's health-guidance body tells hospitals to use the least expensive valve and says the long-term data do not justify paying more - which is the company's position exactly - and it confirms Hydra is one of ten valves on the NHS supply framework. The selling network is real: 21 countries to 35, and more valves sold per country. And a published measure matters clinically - 11.7% of its patients needed a pacemaker afterwards, against 15% to 17% for the two market leaders. What holds the score at 3 is the evidence behind the valve. The company has 252 patients across four studies, none of them randomised, against a competitor's 768-patient randomised trial published in The Lancet. Two national regulators, Taiwan in 2018 and Australia in June 2024, refused this exact valve for want of clinical studies. The company's own paid industry report claims market positions for its stents and its plugs, and none anywhere for its valve. And part of the recent growth was a field being cleared rather than won: Boston Scientific withdrew a competing valve worldwide in May 2025, and a court barred Meril's valve across sixteen European countries from late 2024. The plugs, unlike the valves, are not growing - the company made fewer of them last year than two years ago.

Everything else

22% of revenue · +39% last year - the fastest of the three

The company's own accessories and two own-brand devices, a renal stent and a leg-artery balloon, together with other companies' products it buys in and resells, including imaging equipment for Philips in India and Insight Lifetech in Europe, and a clot-removal system for an American maker in parts of India.

The market3/5

This is the fastest-growing fifth of the company and the least explained part of the document. The markets inside it grow around 6% a year. The real problem is that the document describes this line two ways that cannot both be true: in three places it includes the two own-brand devices, and in a fourth it moves them into the stent business and leaves this line as nothing but accessories. Neither own-brand device appears in the company's capacity table or its list of approvals. Working from the audited purchase figures, we put bought-in goods at roughly a quarter to two-fifths of this line, with the rest being the company's own accessories made on its existing catheter equipment. The document names no reason at all for last year's 39% jump - it gives growth rates for the other two businesses in its own commentary and omits this one - and the growth was not Indian, because India fell while this line rose. What is left to win is small in rupees, and the part that belongs to other people's products is not really the company's to keep.

Right to win2/5

Nothing here stands up as an advantage. The document names no competitor for this line anywhere, claims no share of any market, and discloses no customer, unit or price figure. The one thing that is genuinely real is that four separate companies - including a New York-listed one - chose to rent this company's cardiology sales force in India and Europe rather than build their own, and that is a judgment by people who know the market. But it is the easiest thing here to copy: any competitor with a catheter sales team can be rented the same way, Meril and Relisys have one, and a supplier can take the territory back the moment it is worth having - which is exactly what this company itself did when it bought its own distributors in Spain and Brazil. One earlier partner, Cordis, had a nationwide Indian distribution deal with the company in 2018 and is not mentioned once in these 569 pages.

A balloon that coats the artery with drug instead of leaving a stent

under 1% of revenue · just started - 1,014 units last year

Sironity, a balloon coated with the same drug used on the company's stents, which treats a narrowed vessel and leaves nothing permanent behind. The production line is built and 98% idle.

The market3/5

This is a real and separate market growing about 7% a year, and it matters for one specific reason: India's price ceiling covers stents and not balloons, so this is the one product here that escapes the cap that has held the main business flat. The medical case is genuine but narrow - these balloons have been shown to beat an uncoated balloon when a stent has re-narrowed, and to match a stent in small vessels - rather than being a general replacement for stents. The whole world market is only about USD 536m, about a quarter of this company's own revenue, so even complete success here is worth perhaps Rs 170 to 280 cr. The company has already built capacity equal to 4% to 9% of what the world uses in a year, and can fill it without raising money.

Right to win2/5

The company makes its own balloons and has coated drug onto devices for 25 years, and its catheter line runs at 96% - so it can make these cheaply without new money, and two government grants help. It also chose its clinical trial well, testing the two uses where these balloons have actually been shown to work rather than the broad use where they failed. But the product is approved in India only - it has no European approval, which the approvals table confirms - no trial has finished, 164 patients are still being enrolled, and the document claims no share of anything, in a filing that claims share for everything else. Meanwhile Concept Medical, 20 km away in the same city, sells the same kind of balloon in more than 80 countries with over 100,000 patients treated, and does not appear in the company's competitive tables at all. On the credit side, Abbott, Medtronic, Edwards, Terumo and Meril have no such product.

The next version of the heart valve

not selling yet · not selling yet

A new Hydra valve with an outer skirt to stop leakage around it, and a new delivery catheter. The catheter has European approval; the valve has Indian approval only.

The market3/5

This sells into the same valve market as the existing product, growing at the same moderate rate, and adds no new market of its own. Its purpose is to fix a measured weakness: about 6% of the current valve's patients get a leak around the implant, against 3.4% and 1.6% for the two competitors measured the same way. An outer skirt is what fixes that.

Right to win2/5

Two permissions are not an advantage. The new delivery catheter has European approval and the new valve has Indian approval - the document nowhere claims European approval for the valve itself - and the only clinical evidence is a 40-patient study at 19 Indian centres that India's regulator required rather than the company volunteering. An outer skirt is standard equipment that all three larger competitors shipped years ago, and the competing valve that was withdrawn worldwide last year had one and still missed its target. There is a timing problem that matters more than any of this: adding an outer skirt counts as a significant design change, so the new valve cannot inherit the old European certificate and must go through the newer approval route from the start - which on this company's own record of about 27 months means it cannot reach Europe before late 2028, after the old certificates have expired.

Four new countries: Australia, Taiwan, Canada, Mexico

not selling yet · not selling yet

Approvals the company says it has recently received to sell certain products in four countries, to be served through distributors rather than its own offices.

The market2/5

Checking the four countries' own public registers narrows this considerably. Only the drug-coated stent is approved anywhere among them - in Canada since April 2026 in the company's own name, in Australia since September 2024, and in Taiwan since 2021 along with two balloons, though the Taiwanese approvals are held by another company rather than by this one. The heart valve and the plugs are approved in none of the four, and the document itself discloses that the valve was refused in Taiwan and in Australia. Two of the four are not new markets at all: the company's own country list already shows Mexico and Taiwan. These are four separate small markets where a health service sets the price, growing about 3% a year between them - the slowest thing in the filing - and together they are worth about Rs 1,560 cr, of which a realistic share in three to five years would be Rs 36 to 90 cr. Nothing funds it, since the offer raises nothing, and three of the four countries have no employees. Set against that, the company did genuinely build Europe from 30% to 39% of its revenue in two years, which is the best evidence that it can enter regulated markets - but it did that with six of its own companies, 68 European sales staff and two acquisitions, which is the opposite of the distributor-led approach proposed here.

Right to winnot scored

Also on the books and not scored: specialty balloons, named once with no size or timing; robotic manufacturing and new materials work, which is a capability inside the existing plants rather than a business; and the United States, which is not a plan at all - the company sought American approval for its stent from 2020, spent about Rs 6 cr, and gave up because American stent prices had fallen too far to be worth it. The largest market in the world is closed by the company's own choice, and the document says so.

The numbers that matter

MeasureFY24FY25FY26Reads
Supraflex Cruz revenue (Rs cr)431431450The flagship stent, 37% of all revenue, is flat in rupees over three years. Found in a risk factor, not in the business section.
Heart valves made (units)6861,1261,784Tripled in two years against a market growing under 10%. The strongest number in the filing, and the company made these itself.
Heart-hole plugs made (units)15,0719,77714,564Still below where they were two years ago, in a market growing about 4%. The two halves of that business are moving in opposite directions.
India revenue (Rs cr)314321316Flat for three years and down last year, in the country whose stent share the company leads with. India has fallen from 35% to 26% of revenue.
Europe revenue (Rs cr)266338468Up 39% last year and now 39% of revenue. All the growth is here - which is why the 2027 approval deadline matters as much as it does.
Countries selling the heart valve212735Genuine expansion, and the valves sold per country rose too, from 33 to 51.
Stent plant in use85%82%78%Falling for three years while capacity was raised. Stent volumes grew about 2% a year, so the business's growth came from price and mix rather than from making more.
Share of Indian drug-coated stent volume--about 25%Independent sources put it near 31% around 2021 and still about 31% in late 2024. The company has given back roughly a fifth of its Indian position.

Checked in the filing

What happens next

The full assessment runs on your word: the money, the people, the record and the offer, worked through in detail. The first thing it has to settle is whether the European approvals will be renewed in time, because 39% of revenue turns on it. It is added to this page when it is done.

First look read from the red herring prospectus of 9 October 2026 (569 pages, by section), plus the public medical-device registers of Australia, Canada and Taiwan, Britain's health-guidance body, published clinical trials and guidelines, a credit rating agency's report on the closest Indian competitor, India's drug-price regulator, and outside market data.